Portal de Periódicos da CAPES

Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes

2015; Impact Journals LLC; Volume: 6; Issue: 19 Linguagem: Inglês

10.18632/oncotarget.3921

1949-2553

Chun-ling Dai, Shaolin Ma, Fang Wang, Hong-Yun Zhao, Xing-Ping Wu, Zhen-cong Huang, Zhe‐Sheng Chen, Kenneth K.W. To, Liwu Fu,

Drug-Induced Hepatotoxicity and Protection

// ChunLing Dai 1,* , ShaoLin Ma 1,* , Fang Wang 1 , HongYun Zhao 1 , XingPing Wu 1 , ZhenCong Huang 1 , ZheSheng Chen 2 , Kenneth To 3 and LiWu Fu 1 1 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, China 2 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA 3 School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR * These authors have contributed equally to this work Correspondence to: Liwu Fu, email: // Keywords : lapatinib; ABC transporters; hepatotoxicity; pharmacokinetic Received : February 18, 2015 Accepted : April 08, 2015 Published : April 23, 2015 Abstract Lapatinib has been used in combination with capecitabine or paclitaxel to treat patients with progressive HER2-overexpressing metastatic breast cancer (MBC). Unfortunately, an increased incidence of hepatotoxicity had been reported in the combinational therapy. The aim of this study was to investigate the potential mechanisms of this combinational therapy. We found that the patients receiving lapatinib and paclitaxel treatment showed a higher incidence of hepatobiliary system disorders than those receiving paclitaxel alone. Lapatinib was shown to increase the accumulation of doxorubicin in ABCB1-overexpressing hepatocellular cancer cells and normal liver tissues without altering the protein level of ABCB1. Pharmacokinetic studies revealed that lapatinib could increase the systematic exposure of paclitaxel and doxorubicin. Moreover, the in vivo experiments showed that the levels of alanine aminotransferase and serious hepatocyte injury in the group of lapatinib plus chemotherapeutic agent were significantly higher than those in the group of single chemotherapeutic agent such as paclitaxel or doxorubicin. Our study thus revealed for the first time that the higher incidence of hepatotoxicity during this combinational treatment was due to the increased drug accumulation in hepatocytes mediated by the inhibition of ABCB1 by lapatinib. Appropriate dose adjustment may be needed to optimize the combination therapy.